Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.
Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ. Liesner RJ, et al. Among authors: carcao m. Haemophilia. 2018 Mar;24(2):211-220. doi: 10.1111/hae.13320. Epub 2017 Aug 16. Haemophilia. 2018. PMID: 28815880 Clinical Trial.
Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.
Chowdary P, Carcao M, Holme PA, Jiménez-Yuste V, Lentz SR, Møss J, Poulsen LH, Shen C, Tosetto A, Wheeler A, Santagostino E. Chowdary P, et al. Among authors: carcao m. Res Pract Thromb Haemost. 2019 Jun 11;3(3):542-554. doi: 10.1002/rth2.12220. eCollection 2019 Jul. Res Pract Thromb Haemost. 2019. PMID: 31294338 Free PMC article.
Patterns of joint damage in severe haemophilia A treated with prophylaxis.
Goren R, Pullenayegum E, Blanchette VS, Dover S, Carcao M, Israels SJ, Chan A, Rivard GE, Steele M, Cloutier S, Klaassen RJ, Sinha R, Price VE, Laferriere N, Paradis E, Wu JK, Feldman BM. Goren R, et al. Among authors: carcao m. Haemophilia. 2021 Jul;27(4):666-673. doi: 10.1111/hae.14345. Epub 2021 May 20. Haemophilia. 2021. PMID: 34015166
Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis.
Oomen I, Camelo RM, Rezende SM, Voorberg J, Mancuso ME, Oldenburg J, Carcao M, Matino D, Lillicrap D, Fischer K, Fijnvandraat K, Gouw SC; International Genetic and clinical determinants of the Outcome of Immune Tolerance Induction (GO-ITI) study group. Oomen I, et al. Among authors: carcao m. Res Pract Thromb Haemost. 2022 Dec 20;7(1):100020. doi: 10.1016/j.rpth.2022.100020. eCollection 2023 Jan. Res Pract Thromb Haemost. 2022. PMID: 36891524 Free PMC article.
Long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients.
Mathias M, Abashidze M, Abraham A, Belletrutti MJ, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Lambert T, Kavardakova N, Lohade S, Turea V, Wu JKM, Klukowska A. Mathias M, et al. Among authors: carcao m. Haemophilia. 2023 Jul;29(4):1005-1012. doi: 10.1111/hae.14796. Epub 2023 Jun 19. Haemophilia. 2023. PMID: 37335546 Clinical Trial.
190 results